{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:03:39Z","timestamp":1769598219672,"version":"3.49.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.01531","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T15:07:28Z","timestamp":1581088048000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive Molecular Profiling for Relapsed\/Refractory Pediatric Burkitt Lymphomas\u2014Retrospective Analysis of Three Real-Life Clinical Cases\u2014Addressing Issues on Randomization and Customization at the Bedside"],"prefix":"10.3389","volume":"9","author":[{"given":"Kristyna","family":"Polaskova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Merta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Martincekova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danica","family":"Zapletalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Kyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Mazanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zdenka","family":"Krenova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Jezova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiri","family":"Tuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarmila","family":"Skotakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Cervinkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalibor","family":"Valik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Zdrazilova-Dubska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Noskova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Pal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Slaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Kozakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Neradil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Veselska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Kanderova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ondrej","family":"Hrusak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giannoula Lakka","family":"Klement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Sterba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-hodgkin's lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pbc.20121","article-title":"Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian cooperative study group","volume":"44","author":"Attarbaschi","year":"2005","journal-title":"Pediatr Blood Cancer."},{"key":"B3","volume-title":"A Language and Environment for Statistical Computing.","year":"2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"i422","DOI":"10.1093\/bioinformatics\/btu449","article-title":"Personalized identification of altered pathways in cancer using accumulated normal tissue data","volume":"30","author":"Ahn","year":"2014","journal-title":"Bioinformatics."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1093\/bioinformatics\/btq431","article-title":"A framework for oligonucleotide microarray preprocessing","volume":"26","author":"Carvalho","year":"2010","journal-title":"Bioinformatics."},{"key":"B6","doi-asserted-by":"publisher","first-page":"18735","DOI":"10.18632\/oncotarget.12932","article-title":"Personalized anticancer therapy selection using molecular landscape topology and thermodynamics","volume":"8","author":"Rietman","year":"2017","journal-title":"Oncotarget."},{"key":"B7","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3892\/or.2013.2864","article-title":"EGFR signaling in the HGG-02 glioblastoma cell line with an unusual loss of EGFR gene copy","volume":"31","author":"Skoda","year":"2014","journal-title":"Oncol Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jaci.2014.02.020","article-title":"Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"134","author":"Kracker","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"4982","DOI":"10.1158\/0008-5472.CAN-09-4172","article-title":"Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations","volume":"70","author":"Dan","year":"2010","journal-title":"Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/1078155217743069","article-title":"Fatal graftversus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab","volume":"25","author":"Jim\u00e9nez-Ubieto","year":"2019","journal-title":"J Oncol Pharm Pract."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3389\/fonc.2019.01034","article-title":"Dendritic cell-based immunotherapy in advanced sarcoma and neuroblastoma pediatric patients: anti-cancer treatment preceding monocyte harvest impairs the immunostimulatory and antigen-presenting behavior of dcs and manufacturing process outcome","volume":"9","author":"Hlavackova","year":"2019","journal-title":"Front Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1200\/JCO.2005.01.9083","article-title":"High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation","volume":"23","author":"Forrest","year":"2005","journal-title":"J Clin Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1101\/gad.190678.112","article-title":"Mutant p53: one name, many proteins","volume":"26","author":"Freed-Pastor","year":"2012","journal-title":"Genes Dev."},{"key":"B15","first-page":"2159","article-title":"Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences","volume":"8","author":"Chen","year":"1993","journal-title":"Oncogene."},{"key":"B16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1177\/1947601912462719","article-title":"Gain-of-function activity of mutant p53 in lung cancer through up-regulation of receptor protein tyrosine kinase Axl","volume":"3","author":"Vaughan","year":"2012","journal-title":"Genes Cancer."},{"key":"B17","doi-asserted-by":"publisher","first-page":"16704","DOI":"10.1074\/jbc.M112.443168","article-title":"A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation","volume":"288","author":"Odell","year":"2013","journal-title":"J Biol Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5807","DOI":"10.1158\/0008-5472.CAN-09-4161","article-title":"Dysregulation of p53\/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer","volume":"70","author":"Lin","year":"2010","journal-title":"Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-07-2010","article-title":"Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines","volume":"7","author":"Kondo","year":"2008","journal-title":"Mol Cancer Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e17574","DOI":"10.1371\/journal.pone.0017574","article-title":"Role of p53 serine 46 in p53 target gene regulation","volume":"6","author":"Smeenk","year":"2011","journal-title":"PLoS ONE."},{"key":"B21","doi-asserted-by":"publisher","first-page":"327fs5","DOI":"10.1126\/scitranslmed.aaf3802","article-title":"Eco-evolution of cancer resistance","volume":"8","author":"Klement","year":"2016","journal-title":"Sci Transl Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40259-016-0208-z","article-title":"Combination treatment of patients with BRAF-mutant melanoma: a new standard of care","volume":"31","author":"Simeone","year":"2017","journal-title":"BioDrugs."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.2013.52.1377","article-title":"Combining targeted therapy with immunotherapy in BRAF -mutant melanoma: promise and challenges","volume":"32","author":"Hu-Lieskovan","year":"2014","journal-title":"J Clin Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/ph9020028","article-title":"Targeted therapies for the treatment of pediatric non-hodgkin lymphomas: present and future","volume":"9","author":"Sorge","year":"2016","journal-title":"Pharmaceuticals."},{"key":"B25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/bjh.14665","article-title":"Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma","volume":"181","author":"Eyre","year":"2018","journal-title":"Br J Haematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1586\/17474086.2015.1071663","article-title":"Idelalisib for relapsed\/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes","volume":"8","author":"Davies","year":"2015","journal-title":"Expert Rev Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.18632\/oncoscience.21","article-title":"Theranostic profiling for actionable aberrations in advanced high risk osteosarcoma with aggressive biology reveals high molecular diversity: the human fingerprint hypothesis","volume":"1","author":"Egas-Bejar","year":"2014","journal-title":"Oncoscience."},{"key":"B28","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/520609a","article-title":"Personalized medicine: time for one-person trials","volume":"520","author":"Schork","year":"2015","journal-title":"Nature."},{"key":"B30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/BF02982645","article-title":"Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders","volume":"77","author":"Ogasawara","year":"2003","journal-title":"Int J Hematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/jcb.21405","article-title":"Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells","volume":"103","author":"Fuchs","year":"2008","journal-title":"J Cell Biochem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.1128\/JVI.01703-10","article-title":"Epstein-Barr Virus LMP1 activates EGFR, STAT3, and ERK through effects on PKC","volume":"85","author":"Kung","year":"2011","journal-title":"J Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1182\/blood-2016-02-702530","article-title":"Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients' survival","volume":"128","author":"Huang","year":"2016","journal-title":"Blood."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T14:06:58Z","timestamp":1581430018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":33,"alternative-id":["10.3389\/fonc.2019.01531"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.01531","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"article-number":"1531"}}